.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,605,897

« Back to Dashboard

Claims for Patent: 5,605,897

Title: 2-methyl-thieno-benzodiazepine
Abstract:Olanzapine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Inventor(s): Beasley, Jr.; Charles M. (Indianapolis, IN), Chakrabarti; Jiban K. (Camberley, GB2), Hotten; Terrence M. (Farnborough, GB2), Tupper; David E. (Reading, GB2)
Assignee: Eli Lilly and Company (Indianapolis, IN) Lilly Industries Limited (Basingstoke)
Application Number:08/387,498
Patent Claims: 1. A method of treating a patient suffering from or susceptible to a pathological psychological condition selected from the group consisting of Moderate Mental Retardation; Severe Mental Retardation; Profound Mental Retardation; Autistic disorder; Pervasive Development Disorder NOS; Conduct Disorder, Group Type; Conduct Disorder, Solitary Aggressive Type; Tourette's Disorder; Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Delirium; Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Delusions; Bipolar Disorder NOS; Personality Disorders, Paranoid; Personality Disorders, Antisocial; and Personality Disorders, Borderline; which comprises administering to a patient in need thereof an effective amount of olanzapine, or an acid addition salt thereof.

2. A method of claim 1 wherein the condition is selected from the group consisting of Bipolar Disorder NOS; Personality Disorders, Paranoid; Personality Disorders, Antisocial; and Personality Disorders, Borderline.

3. A method of claim 1 wherein the condition is selected from the group consisting of Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Delirium; and Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Delusions.

4. A method of claim 1 wherein the effective amount is from 1 to 20 mg per day of olanzapine, or an acid addition salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc